{"disease":{"id":"acute-pyelonephritis","name":"Acute pyelonephritis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"atm-avi","indication_name":"Treatment of acute pyelonephritis (APN) caused by Escherichia coli.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute pyelonephritis (APN) caused by Klebsiella pneumoniae.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute pyelonephritis (APN) caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute pyelonephritis (APN) caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"ceftolozane","indication_name":"Acute pyelonephritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zerbaxa","generic_name":"CEFTOLOZANE","company_name":"Cubist Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":"Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"various","indication_name":"Acute pyelonephritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"tazobactam","indication_name":"Acute pyelonephritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zosyn","generic_name":"TAZOBACTAM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":50,"revenue":null,"mechanism":"Zosyn works by blocking bacterial enzymes that break down antibiotics, allowing the antibiotics to kill bacteria more effectively."}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06059846","title":"A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1690,"lead_sponsor_name":"Spero Therapeutics","has_results":true},{"nct_id":"NCT03788967","title":"Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1372,"lead_sponsor_name":"Spero Therapeutics","has_results":true},{"nct_id":"NCT04667195","title":"Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis","phase":"","overall_status":"COMPLETED","enrollment_count":966,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT03840148","title":"Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":661,"lead_sponsor_name":"Venatorx Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05887908","title":"Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":614,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":true},{"nct_id":"NCT02486627","title":"A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":609,"lead_sponsor_name":"Achaogen, Inc.","has_results":true},{"nct_id":"NCT02166476","title":"Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":550,"lead_sponsor_name":"Melinta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04979806","title":"Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"Wockhardt","has_results":false},{"nct_id":"NCT03477422","title":"CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Venus Remedies Limited","has_results":false},{"nct_id":"NCT04686318","title":"Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis","phase":"","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT04594161","title":"Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis","phase":"NA","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT03757234","title":"IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Paratek Pharmaceuticals Inc","has_results":true},{"nct_id":"NCT05060419","title":"Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01096849","title":"A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Achaogen, Inc.","has_results":true},{"nct_id":"NCT05905055","title":"P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT04505683","title":"A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"Sihuan Pharmaceutical Holdings Group Ltd.","has_results":false},{"nct_id":"NCT06141395","title":"NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Hellenic Institute for the Study of Sepsis","has_results":false},{"nct_id":"NCT03445195","title":"Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Entasis Therapeutics","has_results":true},{"nct_id":"NCT01970371","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Achaogen, Inc.","has_results":true},{"nct_id":"NCT04882085","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04682834","title":"Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":false}],"total":21},"guidelines":[{"drug_id":"levofloxacin","guideline_body":"FDA label","recommendation":"Levofloxacin is indicated for the treatment of acute pyelonephritis due to Escherichia coli or Klebsiella pneumoniae.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"levofloxacin","guideline_body":"FDA label","recommendation":"Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"levofloxacin","guideline_body":"FDA label","recommendation":"Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"levofloxacin-in-dextrose-5-in-plastic-container","guideline_body":"FDA label","recommendation":"Levofloxacin is indicated for the treatment of acute pyelonephritis due to specified bacteria.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"levofloxacin-in-dextrose-5-in-plastic-container","guideline_body":"FDA label","recommendation":"Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to specified bacteria.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"levofloxacin-in-dextrose-5-in-plastic-container","guideline_body":"FDA label","recommendation":"Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to specified bacteria.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}